Skip to main content
. 2019 Jun 21;112(4):384–390. doi: 10.1093/jnci/djz127

Figure 4.

Figure 4.

Predicted 20-year cumulative incidence of prostate cancer death for men with prostate-specific antigen between 4.0 and 10.0 ng/mL at screening age 55 or 65 years by biopsy strategy. *IDEAL = ideal biomarker with 100% sensitivity or specificity for any PCa; IDEALhg = ideal biomarker with 100% sensitivity or specificity for high-grade PCa; MiPS = Michigan Prostate Score for any PCa; MiPShg = Michigan Prostate Score for high-grade PCa; PCa = prostate cancer; PCA3 = prostate cancer antigen 3; T2:ERG = TMPRSS2:ERG gene fusion.